Supply issue: isoniazid 100mg with rifampicin 150mg (Rifinah) Tab

We are writing to inform you that Sanofi, the supplier of isoniazid 100mg with rifampicin 150mg (Rifinah) tab, has advised of a supply issue due to delays with manufacturing. The current stock has the expiry date 30 November 2025. 

Key messages:

An alternative brand Rifamazid has been listed (funded) from 1 December 2025. This is an unapproved medicine and as such needs to be prescribed and dispensed in line with section 29 of the Medicines Act. It is estimated it will be available to order mid to late December 2025.

The alternate brand:

• Rifamazid labels and packaging are in Polish.

• The supplier will include an English language Consumer Information Sheet with each box.

• Additional information and a patient information leaflet can be found - Rifinah supply issue on the Pharmac website

Where the combined formulation is not available the single chemical tablets can be used:

• Isoniazid Tab 100 mg (Noumed Isoniazid) Pharmacode 2695901; and

• Rifampicin Cap 150 mg (Rifadin Sanofi) Pharmacode 251186.

We understand that this is not ideal, however, this approach means people can continue to access treatment.

Thank you for your assistance with managing this difficult situation.

Questions:

If you have any queries, please contact us at enquiry@pharmac.govt.nz.

Ngā mihi

Dr David Hughes

Chief Medical Officer | Director Advice & Assessment

Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington

DDI: +64 21 962 317 | P: +64 4 460 4990 |  www.pharmac.govt.nz